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Abstract: In his most celebrated tale “The Picture of Dorian Gray”, Oscar Wilde stated 
that “those who go beneath the surface do so at their peril”. This sentence could be a 
prophetical warning for the practitioner who voluntarily challenges himself with trying to 
synthesize marine sponge-deriving pyrrole-imidazole alkaloids. This now nearly triple-
digit membered community has been growing exponentially in the last 20 years, both in 
terms of new representatives and topological complexity − from simple, achiral oroidin to 
the breathtaking 12-ring stylissadines A and B, each possessing 16 stereocenters. While the 
biosynthesis and the role in the sponge economy of most of these alkaloids still lies in the 
realm of speculations, significant biological activities for some of them have clearly 
emerged. This review will account for the progress in achieving the total synthesis of the 
more biologically enticing members of this class of natural products. 
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1. Introduction  
 
Sometime in 2003, our Company decided to set up a new project based upon the chance of fishing 
out new potent and selective kinase inhibitors from the natural products armoury. Particularly, the task 
was to play with the marine-origin metabolite hymenialdisine (see Subsection 3.1), a natural-born pan-
kinase inhibitor. The goal of that project would have been to first synthesize this pyrrole-imidazole 
alkaloid and then to bias its biological activity through chemical manipulations. A non-biomimetic, 
simple disconnection allowed us to cut off the double bond connecting the northern glycocyamidine 
ring with the southern pyrroloazepinone, thus envisioning aldisine as the suitable key intermediate. 
However, as soon as we were able to routinely produce multigram batches of this intermediate, an 
outstanding paper from Wan et al. [1] (see Subsection 3.1) was published, in which a number of 
hymenialdisine derivatives, even larger than in our rosiest hopes, was synthesized. Despite this 
setback, we pursued anyway the opportunity to successfully complete the hymenialdisine synthesis. 
From then on, the temptation of challenging other pyrrole-imidazole alkaloids was hard to resist, as 
much as it was hard to resist the enjoyment of the stimulating literature dealing with those natural 
products, published during the last five years in exponentially growing numbers.  
The idea of a review recounting the efforts and achievements in the total synthesis of pyrrole-
imidazole alkaloids was actually born from the perusal of these papers. However, as a number of 
reviews dealing with this topic are already available [2–10], we decided to cover the literature from 
2005 to mid-2009 by focusing only on those alkaloids possessing a clear pharmacological value. A 
brief discussion on the biogenesis and the ecological role of these natural products will be the   
hors-d’œuvre. 
 
1.1. Pyrrole-Imidazole Alkaloids Sources and Biogenesis 
 
The pyrrole-imidazole alkaloids (PIAs) family comprises hundreds of secondary metabolites 
originating from marine sponges exclusively. Those natural products, whose architectural complexity 
goes from simple, achiral, monomeric oroidin (1, Figure 1) to the breath-taking 16-stereocenter-
containing tetrameric stylissadine A and B (2 and 3, Figure 1), have been mainly isolated from various 
species of Agelasidae, Axinellidae, Dyctionellidae and Hymeniacidonidae families of sponges [2]. The 
systematic recurrence of PIAs in these families of sponges allowed to speculate their taxon-specificity 
and then to consider these secondary metabolites as chemical markers for phylogenetically related 
sponges [11,12]. The localization of those alkaloids in sponge cells has recently been investigated [13]. 
There are numerous speculations in the literature on the biogenesis of PIAs. As the simple oroidin 
(1, Figure 1) is mostly considered to be the biogenetic precursor of any other alkaloid pertaining to this 
family, those hypotheses can be grouped according to their pre- or post- oroidin focus. Pre-oroidin 
speculations are based on the fundamental aminoacids involved in the production of oroidin in living 
organisms (Figure 2). Thus, proline and/or ornithine may provide the backbone to build up the pyrrole-
2-carboxylic acid moiety, while histidine may contribute to the 2-aminoimidazole portion. Low 
incorporation of these three aminoacids in the biosynthesis of the oroidin cyclized derivative 
stevensine has been experimentally observed by Kerr et al. by feeding cell cultures of the marine 
sponge  Axinella corrugata (previously Teichaxinella morchella) with the corresponding   Mar. Drugs 2009, 7 
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14C-labeled aminoacids [14]. Alternatively, ornithine [11,12] as well as lysine [15] may be the source 
of the the five contiguous carbon atoms present in the aminopropenylimidazole portion of oroidin. A 
more recent and intriguing hypothesis emerged upon the isolation of verpacamides A-D (e.g. 
verpacamide C, 4, Figure 2) from the marine sponge Axinella vaceleti [16].  
 
Figure 1. PIAs complexity extremes. 
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These cyclo(L-Arg-L-Pro) dipeptides differ only by their oxidative state, thus resembling 
intermediates along a given biogenetic pathway. The authors, by capitalizing on the discovery of an 
unprecedented conversion of proline into 2-aminoimidazolone [17], speculate that verpacamides may 
represent the biogenetic precursors of dispacamide A (5, Figure 2), a postulated forerunner of oroidin. 
Post-oroidin hypotheses, on the other hand, can be sub-classified according to the alkaloids and 
their respective biosynthesis. Thus, along with a number of biochemical considerations on single 
natural products, frequently formulated while disclosing their isolation [18–28], more general 
speculations that try to link as many PIAs as possible have emerged. The seminal paper in this respect 
was published in 2001 by Al Mourabit and Potier (A/P) [29]. The ability of a given enzyme, through 
proton exchange reactions, to govern the tautomeric equilibria (and consequently the corresponding 
nucleophilic/electrophilic behaviour) of the aminopropenylimidazole portion of oroidin, was 
hypothesized to be the key point for the formation of both polycyclic monomers and cyclized dimers. 
The common intermediate (6, Figure 2) arising from oroidin that the authors invoked for the formation 
of the palau’amines, the styloguanidines and the axinellamines groups of alkaloids (see Section 5), was 
subsequently elaborated by Köck, Baran et al. (K/B) from both a stereochemical and an oxidative state 
point of view [30], in light of the recently revised structure of palau’amine (see Section 5). The 
symmetry that this revision finally brought to the cyclized dimeric members of the PIAs family, 
allowed the so-called “pre-axinellamines” intermediate (7, Figure 2) not only to more precisely 
connect the aforementioned groups of natural compounds, but also to include the konbu’acidins and 
the subsequently isolated massadines and stylissadines in this network. According to the same Mar. Drugs 2009, 7 
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hypothesis, the “pre-axinellamines” 7 may be derived, in turn, from oroidin (1), sceptrin (8, Figure 2) 
or from ageliferin (9, Figure 2) [30]. Interestingly, the amide hydrolysis that Köck, Baran et al. 
invoked in order to cleave redundant bromopyrrole moieties in the styloguanidine and palau'amine 
biosynthetic hypothesis (see Section 5) [30], is in agreement with the supposition that the   
4,5-dibromopyrrole-2-carboxylic acid derives from oroidin hydrolysis, and is not one of its   
precursors [17]. 
 
Figure 2. PIAs biogenetic speculations. 
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If, on the one hand, nothing is known about either the enzymes or the corresponding genes by 
which sponges perform the aforementioned biogenetic transformations, on the other hand, 
haloperoxidase-mediated introduction of halogen(s) onto those marine alkaloids are easy to be 
inferred. Those enzymes, whose cofactors are represented by heme iron or vanadium, employ 
hydrogen peroxide to generate a metal-bound hypohalite ion, that is the electrophilic halogen source 
responsible for the halogenation of electron-rich substrates like the pyrrole nucleus in PIAs [31,32]. 
Other, recently discovered, haloperoxidases (e.g., PrnA) use flavin adenine dinucleotide as a metal-
free cofactor to halogenate nucleophilic substrates [33]. 
The absolute configuration of many of the more complex members of the PIAs family is still not 
known. Despite the fact that tentative assignment through CD spectroscopy (for a recent example, see Mar. Drugs 2009, 7 
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Nishimura et al. [34]) for some of the simpler representatives has proven to be correct [35–37], only 
total synthesis can tell us which enantiomer is the natural one.  
 
1.2. Pyrrole-Imidazole Alkaloids Ecological Role 
 
PIAs’ ecological role started to be investigated in the late ‘90s, when it was realized that sponges’ 
structural defences alone (spongin fibers and glass spicules) were ineffective feeding deterrents 
towards predatory reef fishes. The first report in this respect dates back to 1996, when an ecoassay-
guided isolation, performed on the extracts of sponges of the genus Agelas, allowed the identification  
of 4,5-dibromopyrrole-2-carboxylic acid and oroidin (1) as the major components responsible for the 
observed chemical feeding deterrence [38]. Later on, stevensine, present in high concentration in the 
sponge Axinella corrugata (previously Teichaxinella morchella), was also demonstrated to possess 
antifeedant properties [39]. A structure-activity antifeedant relationship was subsequently established 
for oroidin-like molecules [40]. From these studies, the imidazole moiety, while not being active per 
se, looks like an enhancer of the deterrent activity exerted by the pyrrole counterpart. Other PIAs were 
recognized to chemically defend sponges from predators [41]. Acquarium and field feeding assays 
unveiled sceptrin (8) as the major metabolite of Agelas conifera able to deter fish feeding at natural 
concentrations, and it allowed ranking of a number of PIAs according to their antifeedant activities. 
This work, furthermore, highlighted the experimental observation that a higher number of bromine 
atoms present in the metabolite correlates with a higher feeding deterrent potency [42]. The ecological 
role of PIAs has been tentatively explained by a general interaction of those metabolites with the 
cellular calcium homeostasis [43,44]. From all those information, indicating that PIAs play a defensive 
role in sponges’ economy, still something is missing in our understanding. Combinations of PIAs did 
not provide any evidence of synergic activity [40]. Concentrations of some PIAs in the sponges are so 
low to have negligible deterrent effects [40,42]. Thus, the spontaneous question remains unanswered: 
“Why do sponges synthesize such a large number of alkaloids?” 
 Moreover, the isolation of both (+)-dibromophakellin (from Pseudoaxynissa cantharella [45]) and 
(-)-dibromophakellin (from Phakellia flabellate [25]) as well as (+)-dibromoisophakellin (from 
Pseudoaxynissa cantharella [45]) and (-)-dibromoisophakellin (from Acanthella carteri [46]) further 
complicates the scenario. As evolutionary pressure should select which enantiomer is better to perform 
a given function, do these enantiomeric alkaloids have a different ecological role in the biology of the 
sponge? 
 
1.3. Pyrrole-Imidazole Alkaloids Classification 
 
The 2-amino-4(5)-vinylimidazole portion of PIAs can vary with regard to its oxidative as well as 
hydration state, while the pyrrole-carboxamide moiety structural variations reside exclusively in the 
absence or the presence of bromine atom(s) in 2- and/or 3- position(s) of the pyrrole nucleus. The most 
commonly accepted PIA classification [2,9] is based upon both the number of “oroidin units” and the 
presence of extra-rings involving either the imidazole or the pyrrole portion of the alkaloids. 
Accordingly, five classes of PIAs will be encountered in the following sections: 
 Mar. Drugs 2009, 7 
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(1) Acyclic  monomers 
(2) Cyclic  monomers 
(3) Acyclic  dimers 
(4) Cyclic  dimers 
(5) Cyclic  tetramers 
Alkaloids whose structures hardly fit any of the aforementioned classification criteria have been 
included in a sixth additional class. 
 
2. Acyclic Monomers 
 
2.1. Oroidin 
 
Oroidin (1) was isolated in 1971 from the marine sponge Agelas oroides [47]. It is the simplest 
among bromopyrrole-imidazole alkaloids and it has a linear structure characterized by a bromopyrrole 
carboxamide and an amino-imidazole moiety linked through a propenyl chain. Oroidin is the most 
abundant PIA and, as already mentioned (Subsection 1.1), it might be considered a biogenetic 
precursor of the other alkaloids. 
Efforts towards the synthesis of oroidin followed two main strategies [2] employing either an 
already assembled imidazole ring [48–50] or an open chain precursor of imidazole [51,52]. In 2006, 
two total syntheses of oroidin were published, and both works have been recently reviewed [10]. 
Ando  et al. [53] described a method involving a versatile intermediate 10, arising from   
2-aminoimidazol-4-carbaldehyde, that allowed the synthesis not only of oroidin (1) and hymenidin 
(11), but also dispacamide A (5) and dispacamide B (12). The general approach of the synthesis is 
reported in Scheme 1, while in Subsection 2.2 a full detailed version is described for the dispacamides. 
 
Scheme 1. Approach to oroidin and related compounds via intermediate 10. 
N
N
NHBoc
OHC
Boc
N
N
NH
Boc
N
O
N
H
N
NH2 H
N
O
O
HN
Br
R
R = Br  dispacamide A (5)
R = H  dispacamide B (12)
N
H
N
NH2 H
N
O
HN
Br
R
R = Br  oroidin (1)
R = H  hymenidin (11)
+
N
N N
N
Ph
S
N
O
O
O
O
NaHMDS 10
Boc
O
 
 
Al Mourabit et al. [54], inspired by the natural product dibromoagelaspongine [19], performed a 
one-pot bromine-mediated oxidative addition of 2-aminopyrimidine, as a masked guanidine, on   Mar. Drugs 2009, 7 
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N-acyl-1,2-dihydropyridine 13. The synthesis proved to be short and exquisite, with only little mass 
loss and good final yields (Scheme 2). 
 
Scheme 2. The Al Mourabit synthesis of oroidin. 
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The function of oroidin (1) as chemical defense for sponges of the genus Agelas against predation 
by the reef fish Thalassomia bifasciatum has already been mentioned (see subsection 1.2). Besides, 1 
inhibits larval metamorphosis of the barnacle Balanus amphitrite (ED50 = 15 μg/mL) [21]. Oroidin was 
also reported to possess antibiofilm activity against the marine α-proteobacteria R. salexigens [55] and 
the medically relevant γ-proteobacterium Pseudomonas aeruginosa (PA; IC50 = 190 μM on PA01;  
IC50 = 166 μM on PA14) [56]. With the aim of finding new chemical entities able to inhibit the 
formation of bacterial biofilms [57–59], the simple and linear oroidin was proposed as a lead 
compound for SAR studies. Melander’s group synthesized several libraries of analogues based upon 
the oroidin template and the 2-aminoimidazole moiety (Figure 3). 
 
Figure 3. Examples of oroidin modification towards antibiofilm inhibitors. 
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Reverse amides [60,61], N-pyrrole substitutions [62], amide isosters [63] and linker modifications 
[64] are only few examples of a huge and successful synthetic work that led to the discovery of small 
molecules able to inhibit and disperse biofilms across order, class and phylum. 
 
2.2. Dispacamide A 
 
In dispacamide A (5), isolated in 1996 by Fattorusso et al. [65] from the sponge Agelas dispar, the 
oroidin 2-aminoimidazole moiety is oxidized to an alkylidene glycocyamidine. Dispacamide A is a 
potent, non competitive, antihistaminic agent, showing activity in the micromolar range on the guinea 
pig ileum [36,65] (pD2 5.52 ± 0.11, where pD2 is the negative logarithm of the molar concentrations of 
the antagonists which induced a 50% decrease in the maximal response to the agonist). It also shows 
fish feeding deterrence (10 mM) [40]. 
Length and functionalization of the central linear chain are crucial parameters for the antihistaminic 
activity, whereas the presence of a bromine atom at position 2 of the pyrrole ring is not relevant. From 
a biogenetic point of view, dispacamide A is assumed [66] to be the direct precursor of 
pyrroloazepinone hymenialdisine (see Subsection 3.1). 
Several total syntheses of dispacamide A have hitherto been reported [51,66,67] and reviewed [4], 
in particular by Lindel et al. [2]. More recently, Ando et al. published a novel approach, which is 
described in Scheme 3 and was already mentioned in the oroidin subsection (see Scheme 1) [53]. In 
Ando’s strategy, the pyrrole part of the congeners for natural 2-aminoimidazole alkaloids was 
introduced at a later stage of the synthesis. 
 
Scheme 3. Ando’s synthesis of dispacamide A. 
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3-Bromo-1,1-dimethoxypropan-2-one and tert-butoxy-carbonylguanidine produced the 
functionalized aminoimidazole ring 14 in acceptable yield, which was then manipulated to furnish the 
suitably protected key intermediate 1,2-bis-tert-butoxycarbonylaminoimidazol-4-carbaldehyde (10). 
The two building blocks 10 and 15 were then coupled via Julia olefination thus providing E olefin 
16 in good yield and good selectivity. From 16, the syntheses of oroidin (1) and hymenidin (11) were 
achieved (steps not shown), while hydrogenating the double bond paved the way for the preparation of 
dispacamides A (5) and B (12). The imidazole nucleus was oxidized with tetra-n-butylammonium 
tribromide and the primary amino group needed to be selectively Boc-protected for ease of 
purification. Final amidation with trichloroacetyl-pyrroles led to the desired dispacamides and could 
be used (in principle) to readily prepare derivatives with structural motifs differing from those 
involved in the natural products. 
 
3. Cyclic Monomers 
 
3.1. Hymenialdisine 
 
(Z)-Hymenialdisine [(Z)-HMD; 17, Figure 4] is the only PIA potently active as kinase inhibitor. As 
it showed nanomolar kinase inhibitory activity against a wide panel of kinases [68], it is potentially 
useful not only for the treatment of cancer, but also for illnesses such as Alzheimer’s disease and type 
2 diabetes. 
 
Figure 4. Structures of HMD and DBH. 
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Nguyen and Tepe [69] recently published a review offering an exhaustive overview on several 
aspects of these molecules. (Z)-HMD (17) was originally isolated from marine sponges of the genera 
Hymeniacidon, Acanthella, Axinella, and Pseudoaxinyssa, while (Z)-2-debromohymenialdisine (DBH) 
(19) came from the sponge Phakellia [70]. 
(Z)-Hymenialdisines differ only by the presence of a bromine atom in the pyrrole α-position; these 
compounds share a fused bicyclic pyrrole[2,3-c]azepin-8-one linked through a double bond with a 
glycocyamidine ring. A few groups contributed to characterize HMD and DBH with spectral and  
X-ray studies [11,71,72]. 
Both the (E) and (Z) isomers have been isolated; they interconvert in a pH- and concentration-
dependent manner [73] and (Z)-HMD (17) is the most abundant one, due to its higher 
thermodynamical stability. Mar. Drugs 2009, 7 
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Synthetic approaches [74–78] towards (Z)-HMD (17) and (Z)-DBH (19) have been reported 
(Scheme 4). 1-Benzoyl-2-methylsulfanyl-1,5-dihydroimidazol-4-one (21) employed in Papeo’s 
approach was also useful in the first total synthesis of (Z)-axinohydantoin (see Subsection 3.2). 
 
Scheme 4. Synthetic approaches to (Z)-HMD (17) and (Z)-DBH (19). 
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Initially (Z)-HMD (17) was found to be slightly cytotoxic in PV4 cells (32.5% at 100 μg/ml) [79]. 
Meijer et al. extensively studied 17 from a structural and biological point of view [68]. (Z)-HMD was 
found to be a competitive inhibitor of ATP (Ki = 50 nM) and it proved to be a potent inhibitor of 
kinases like Cyclin-Dependent Kinases, Glycogen Synthase-3β and Casein Kinase 1 (Table 1). 
 
Table 1. Kinase inhibition selectivity of 17. 
Enzyme IC50 (nM)  Enzyme  IC50 (nM) 
CDK1/cyclin B  22  Erk 1  470 
CDK2/cyclin A  70  Erk 2  2000 
CDK2/cyclin E  40  c-raf  >10,000 
CDK3/cyclin E  100  MAPKK  1200 
CDK4/cyclin D1  600  GSK-3β 10 
CDK5/p25 28  CK1  35 
CDK6/cyclin D2  700  CK2  7000 
 
The structure of a CDK2-HMD complex was determined at 2.1 Å resolution, indicating the binding 
of 17 in the ATP binding pocket [68]. The N1 atom of the pyrrole ring, the carbonyl oxygen and the 
amide nitrogen of the azepine ring form three hydrogen bonds with Glu81 and Leu83 of the CDK2 
backbone. The pyrroloazepine bicyclic core is held in a shallow hydrophobic pocket by several van der Mar. Drugs 2009, 7 
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Waals contacts with side chain atoms (31 of total 45). The bromine is partially exposed to the solvent 
and also packed against a few main-chain residues. In addition, the free NH2 group is involved in 
direct hydrogen bond formation with Asp145, while the glycocyamidine ring system makes other Van 
der Waals interactions together with two water-mediated hydrogen bonds with the main chain.  
In spite of this high in vitro activity, 17 did not show significant inhibition in cells: only 40% of 
growth inhibition was reached at 100 μM in adenocarcinoma cells [1]. This behaviour might be 
ascribed to the low permeability of the molecule. 
However, being potent pan-kinase inhibitors, HMD and analogues represent a potential for the 
treatment of neurodegenerative disorders, inflammatory pathologies, diabetes and cancer. Different 
series of HMD analogues were synthesized in order to establish a SAR [1,80,81]. In those derivatives, 
the main features that allow (Z)-HMD to bind in the kinase ATP binding site were left unchanged, 
while attempts have been performed in order to improve selectivity and permeability [82–84]. 
 
3.2. Axinohydantoins 
 
(E)-Axinohydantoin (23) and (E)-debromoaxinohydantoin (25) were isolated from the sponges 
Axinella sp. [85] and Monanchora, respectively (genera Hymeniacidon) (Figure 5) [86]. (Z)-
Axinohydantoin (22) and (Z)-debromoaxinohydantoin (24) were subsequently isolated from the 
sponge  Stylotella aurantium [87]. Those latter secondary metabolites were also found in 
Hymeniacidon species (Figure 5) [88]. 
 
Figure 5. Axinohydantoins. 
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Axinohydantoins are structurally related to HMD, but, in the former, the glycocyamidine ring is 
replaced by a hydantoin ring. While 22 displayed interesting micromolar inhibitory activity against a 
number of kinases (PKC, IC50 = 9 μM; GSK-3β, IC50 = 3 μM; CDK1/cyclin B, IC50 = 4 μM; CK1, 
IC50 = 4.5 μM; CDC5/p25, IC50 = 7 μM) [6,68,87], 24 inhibits, always in the micromolar range, only 
protein kinase C (IC50 = 22 μM). In addition, a slight activity was found on murine P388 lymphocytic 
leukemia for (E)-axinohydantoin (23) (ED50 of 18 μg/mL) [85]. 
The first total syntheses of 24 and 25 were reported by Horne et al.  [89]. Recently our group 
accomplished the first synthesis of (Z)- and (E)-axinohydantoins (22) and (23), along with a second 
generation synthesis of 24 and 25 [90]. To this purpose, the chemistry already optimized for HMD 
synthesis [78] was successfully employed. Mar. Drugs 2009, 7 
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Aldisine (26) and 2-bromoaldisine (27), available in multigram scale, were coupled with the 
versatile intermediate 1-benzoyl-2-methylsulfanyl-1,5-dihydroimidazol-4-one (21) to afford 
intermediates 28 and 29, which were readily converted to the corresponding hydantoins 30 and 31 
(Scheme 5). 
 
Scheme 5. Northern ring installation. 
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Intermediates 28 and 29 are also potentially suitable for preparing new analogues via nucleophilic 
displacement of the methylthio group. The cleavage of the benzoyl protecting group and the slow 
double bond endo/exo isomerization sequentially occurred in the presence of NH2NH2·H2O, thus 
delivering debromoaxinohydantoins (82% overall yield, 24/25 ratio: 90/10) and axinohydantoins (67% 
overall yield, 22/23 ratio: 80/20), respectively [90] (Scheme 6).  
 
Scheme 6. Benzoyl removal and double bond isomerization. 
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3.3. Dibromophakellstatin 
 
(-)-Dibromophakellstatin 32 is a tetracyclic monomeric pyrrole-imidazole alkaloid, isolated from 
the Indian Ocean sponge Phakellia mauritiana in 1997 by Pettit et al., that showed interesting cell 
growth inhibitory activity against a minipanel of human cancer cell lines [91]. Since then, several total 
syntheses of the racemic natural product have been reported and reviewed [3,7,8,10]. The approaches 
by Lindel [92,93], Feldman [94,95], Austin [96] and Chen [97] for the construction of the tetracyclic 
core of rac-dibromophakellstatin are summarized in Scheme 7. 
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Scheme 7. Racemic approaches to (±)-dibromophakellstatin 32. 
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The first total synthesis of (-)-dibromophakellstatin 32 was accomplished by the Lindel group [98], 
who exploited the enantioselective version of their three-component imidazolinone annulation on a 
tricyclic enamide with TsONHCOOEt
 [92,93] (Scheme 8). Hydroxyproline was chosen as source of 
stereogenic information and used for the synthesis of chiral enamide 33, where the TBS-protected 
hydroxy group, positioned in the preferred axial conformation, efficiently controlled the 
stereochemistry of the annulation, thus affording intermediate 34 as single diastereoisomer. The 
endgame to the natural product was put through by the reductive removal of hydroxy group after its 
conversion into alkylbromide 35 and treatment with SmI2 that, simultaneously, reduced the C-Br bond 
and deprotected imidazolone nitrogens to 36. Final bromination with NBS afforded   
(-)-dibromophakellstatin 32. 
 
Scheme 8. Enantioselective synthesis of (-)-32. 
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In late 2007, a careful investigation of the antitumor activity of dibromophakellstatin both as 
racemic mixture and as single enantiomers has been reported by Lindel [99]. Rac-dibromophakellstatin 
was tested on a panel of 36 human tumor cell lines and proved to be active on ovarian   
(IC50 = 0.60 μM), glioblastoma (0.93 μM), non-small cell lung (0.96 μM) and uterus (1.21 μM) cancer 
cell lines. When inhibitory activity against these cell lines was tested for single enantiomers, only  
(-)-32 showed antitumor effects. 
 
3.4. Agelastatins 
 
Four closely related compounds belong to this class of tetracyclic PIAs. Agelastatin A (37) and its 
brominated congener agelastatin B (38) were isolated in 1993 [20] from the marine sponge Agelas 
dendromorpha by Pietra and co-workers. They were fully characterized by using a combination of 
molecular modelling, NMR and exciton splitting [100]. Few years later two new metabolites, namely 
agelastatin C (39) and agelastatin D (40) were isolated from the extracts of the sponge Cymbastela sp. 
by Molinski and co-workers [101] (Figure 6). 
 
Figure 6. Agelastatins. 
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These natural products display a densely functionalized tetracyclic core with four contiguous 
stereocenters, which is an enticing and synthetically challenging structural motif. Agelastatin A (37) is 
reported to exhibit significant biological activity [9]. After its recognition as cytotoxic agent towards 
KB cells at concentration below 1 μg/mL [20], Pietra and Pettit research groups showed a powerful 
activity of 37 against a wide range of cancer cell lines such as human KB nasopharyngeal cancer cells, 
L1210 murine tumor cell line, RT112/84 bladder carcinoma cells, SK-MEL-5 melanoma cells,   
HCT-116 colon carcinoma cells, and MDA-MB-435s breast cancer cells [37,68,102]. Comparative 
studies showed that agelastatin A inhibited tumor cell growth from 1.5 to 16 times more potently than 
cisplatin, particularly, against human bladder, skin, colon, and breast carcinomas [103]. 
Very recently, agelastatin A (37) was demonstrated to be very effective in down-regulating the 
expression of β-catenin and in up-regulating Tcf-4, an inhibitor of osteopontin (OPN) at the cellular 
level. These two effects result in repression of OPN and inhibition of OPN-mediated malignant cell 
invasion, adhesion, and colony formation in vitro [104]. Longley also highlighted that agelastatin A’s 
ability in inhibiting β-catenin, which also controls transcription from the multidrug resistance 1 gene 
[105], could be helpful in reducing drug resistance issues, possibly both as single agent as well as in 
combination therapy. Together with its cytotoxic activity, agelastatin A was also envisioned as Mar. Drugs 2009, 7 
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inhibitor of glycogen synthase kinase-3 β (GSK-3β), an enzyme responsible for the neurofibrillary 
tangles typically found in Alzheimer’s disease, and as a mimetic of insulin [106]. 
The impressive biological activity, together with its scarce availability, prompted many synthetic 
chemists to engage in the total synthesis of 37. To date, fourteen total syntheses have been achieved, 
each presenting different strategies to assemble the tetracyclic core of agelastatin A [11,107–111]. 
In analogy to the previously published papers, the most recently reported syntheses of 37 show very 
different and elegant retrosynthetic analyses which represent a clear example of the creativity in the 
“art of total synthesis” [112]. The key structures involved in the achievement of agelastatin A 
synthesis are represented in Figure 7. 
 
Figure 7. Different synthetic routes to achieve agelastatin A total synthesis. 
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Trost and Dong applied a metal-catalyzed asymmetric allylic alkylation (AAA) [113] to the 
synthesis of 37 by using pyrroles and N-alkoxyamides (hydroxamic esters) as nucleophiles [114,115]. 
Key intermediate 43 was obtained using an AAA between bisallylic carbonate 41 and the bifunctional 
nucleophile 42. The challenging task, aimed at chemoselectively differentiating the two nucleophilic 
nitrogens in 42,  successfully allowed a tandem cyclization to obtain pyrrolopiperazinone 44  
(Scheme 9). 
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Scheme 9. Tandem Pd-AAA reported by Trost and Dong.  
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The Kresze reaction was used to carry out an allylic amination on 44. Subsequent treatment of 45 
with methyl isocyanate gave urea 46 (Scheme 10).  Hydroboration  followed by NaBO3-mediated 
peroxidation gave alcohol 47 which, after Dess-Martin periodinane (DMP) oxidation and protective 
group removal, afforded (-)-37. 
 
Scheme 10. Completion of the Trost (-)-agelastatin A synthesis. 
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Ichikawa and co-workers achieved the total synthesis of (-)-37 by using a strategy involving a [3.3] 
sigmatropic rearrangement of an allyl cyanate as the key step [116]. The synthesis started with an 
elegant transformation of L-arabitol 48 to obtain allyl carbamate 49. Subsequent dehydration afforded 
allyl cyanate 50, which rearranged to 51 with a [1,3] chirality transfer of the stereogenic center via a 
concerted six-membered transition state (Scheme 11).  
 
Scheme 11. Allyl cyanate [3.3] sigmatropic rearrangment involving a [1,3] chirality transfer. 
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Further manipulations gave compound 52, which was in turn subjected to ring-closing metathesis 
using first generation Grubb’s catalyst thus securing cyclopentene 53. Introduction of the carbamate 
functionality followed by its dehydration delivered a substrate prone to a subsequent [3.3] sigmatropic 
rearrangement which, after isocyanate trapping, gave the vicinal diamine 54 (Scheme 12). The total 
synthesis of (-)-37 was then completed in eight steps. 
 
Scheme 12. Access to key vicinal diamine 54. 
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Yoshimitsu, Ino and Tanaka [117] reported the total synthesis of 37 starting from enantiomerically 
pure aminoalcohol 55 which was converted in the pivotal azidoformate 56 in five steps (Scheme 13). 
Vicinal dinitrogen functionalities were introduced through thermal aziridination of the π-bond 
followed by ring opening, thus obtaining azide 57. Lactamization proceeded smoothly after azide 
reduction and nitrile hydrolysis affording carbamate 58, which was opened using methylamine. The 
resulting alcohol was carefully oxidized using TPAP, and the derived ketone was trapped in situ by the 
vicinal urea nitrogen. This extremely concise synthesis was completed via pyrrole bromination 
(Scheme 13).  
 
Scheme 13. Aziridination reaction used in agelastatin A synthesis. 
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One year later the same research group proposed a second-generation approach affording a 
streamlined process to obtain agelastatin A (37) [118]. This synthesis is  based on an iron halide-
triggered radical aminohalogenation. Intermediate 59 was considered the most suitable substrate 
because of its restricted mobility, which might improve the stereochemical outcome of the reaction 
during the halogen transfer step. After extensive investigations, the authors reported that the best 
results were achieved by performing the reaction in ethanol with FeBr2 as radical initiator in the 
presence of bromide salts, such as LiBr or Bu4NBr. Azidoformate 59  was thus treated under the 
abovementioned conditions delivering bromide 60 in satisfactory yield, which was in turn reacted with 
NaH in DMF affording lactam 58. Agelastatin A (37) was finally obtained in further three steps as 
outlined below (Scheme 14). 
 
Scheme 14. Yoshimitsu and Tanaka’s second-generation approach to (-)-37.  
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Intramolecular olefin aziridination was used in 2009 by Wehn and Du Bois [119] to forge 
agelastatin A. In their synthesis, sulfamate 61, easily prepared starting from commercially available 
materials, was subjected to aziridination in the presence of dimeric Ru
II catalyst in order to obtain 62, 
which was then regioselectively opened to give oxathiazepane 63. Interestingly, the catalyst was 
reported to be very effective, allowing very low loading (0.06 mol%) and high turnover number 
(>1500) thus enabling an easy and inexpensive scale-up. Key polyamine intermediate 64 was secured 
from 63 by treatment with ethylpyrocarbonate and then with NaSePh (Scheme 15). 
 
Scheme 15. Synthesis of selenide key intermediate 64. 
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After construction of the central core, agelastatin A was obtained in seven steps. Racemic 37 was 
recently prepared by Dickson and Wardrop [120] using a synthetic route in which a trichloroacetamide 
group plays the simultaneous role of a protecting group, a pendant nucleophile assisting the 
cyclofunctionalization and the latent urea required for the imidazolinone ring construction. The key 
compound all cis-substituted cyclopentene 68 has been obtained starting from the imidate 65, which 
after heating in xylenes, gave, through Overman rearrangement, trichloroacetamide 66. Compound 67 Mar. Drugs 2009, 7 
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was obtained upon treatment with N-bromoacetamide followed by DBU-mediated debromination. 
Exposure of dihydrooxazole 67 to p-toluenesulfonic acid gave key compound 68 (Scheme 16). 
 
Scheme 16. Synthesis of all cis-substituted cyclopentene 68. 
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Advanced intermediate 69 was easily obtained from 68 by converting the hydroxy group into the 
corresponding phthalimide under Mitsunobu conditions followed by installation of the urea moiety 
through displacement of the trichloroacetamide group. Tricycle 70 was forged by hydrazine-mediated 
phthalimide removal, coupling with 2-pyrrole carboxylic acid, acetate ester methanolysis, oxidation 
and base-mediated intramolecular cyclization. This synthesis was completed by removing the benzyl 
group with simultaneous imidazolidinone ring formation. Regioselective pyrrole bromination afforded 
(±)-37 (Scheme 17). 
  
Scheme 17. Completion of (±)-37 synthesis according to Dickson and Wardrop. 
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Chida and co-workers [121] envisioned diaminocyclopentene 74 as key intermediate for their 
agelastatin A synthesis. In order to obtain 74, bis-trichloroimidate 71, prepared in seven steps from 
commercially available D-tartaric acid, was subjected to a sequential Overman rearrangement. Allylic 
sulfide 72 thus obtained was oxidized to sulfoxide and, in the presence of P(OMe)3, underwent the 
Mislow-Evans rearrangement to diolefin 73. Grubbs’ catalyst provided smooth access to 74, which 
was finally converted into oxazoline 75 (Scheme 18). 
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Scheme 18. Synthesis of key compound 75. 
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Removal of the trichloroacetyl group in 75 with DIBAL, condensation of the resulting amine with 
2-bromopyrrol-5-yl carboxylic acid, followed by hydrolysis of oxazoline and THP protection of the 
secondary alcohol afforded 76. In order to carry out the aza-Michael addition to construct the 
piperazinone ring, intermediate 76 was converted into protected N-methylurea 77 by treatment with 
2,4-dimethoxybenzylmethyl amine (MeNHDMB). Removal of THP and oxidation of the secondary 
alcohol gave α,β-unsaturated ketone 78  which, in turn, underwent the final aza-Michael addition. 
Targeted (-)-37  was isolated  in satisfactorily yield after oxidative cleavage of DMB group   
(Scheme 19). 
 
Scheme 19. Chida and co-workers completion of (-)-37 total synthesis. 
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4. Acyclic Dimers 
 
4.1. Nagelamide D 
 
Nagelamide D (79) [122] has a connection between C-10 and C-15’ of its oroidin monomer units 
and was isolated as a racemate by Kobayashi’s group in 2003 from Okinawan marine sponges of the 
genus  Agelas. Some antibacterial activity was reported against Micrococcus luteus (MIC,  
4.17  μg/mL),  Bacillus subtilis (MIC, 33.3 μg/mL) and Escherichia coli (MIC, 33.3 μg/mL). 
Nagelamide D (79) was synthesized by Lovely group [123] in 2009 according to the retrosynthetic 
pathway depicted in Scheme 20. The envisioned strategy foresees a cross-coupling reaction between 
imidazolyl fragment A and vinyl fragment B, both accessible from a common precursor, the protected  
diiodoimidazole 80 [124]. 
 
Scheme 20. Retrosynthetic approach to Nagelamide D (79). 
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The two actual fragments 81 and 82 were coupled according to the Baldwin procedure [125] for 
fluoride-mediated Stille reaction, providing bis-vinylimidazole 83 in good yield after treatment with 
TBAF to complete the partial desilylation. The next step was a catalytic hydrogenation to saturate both 
double bonds (Scheme 21). 
 
Scheme 21. Nagelamide D: Fragment Assembly and Reduction. 
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Diol 84 was then protected as bis tbutyl-dimethylsilylether 85 and then transformed into the bis 
azide 86, before desilylation of the hydroxy groups with TBAF (Scheme 22). At this point, the two 
bromopyrrole moieties were introduced by means of a double Mitsunobu reaction with 
dibromopyrrolohydantoin derivative 87, which completed the formation of the nagelamide D full 
skeleton. The pyrrolohydantoin rings were then hydrolyzed, followed by imidazole deprotection with 
methanolic HCl. Azides were finally reduced over Lindlar catalyst affording nagelamide D (79), which 
was isolated as its TFA salt.  
 
Scheme 22. Completion of the synthesis of nagelamide D (79). 
N
N
N
N
DMAS
DMAS
OTBS
OTBS
N
N
N
N
DMAS
DMAS
OH
OH
TBSCl
 imidazole
90%
CH2Cl2
N
N
N
N
DMAS
DMAS
OH
OH
N3
N3
HN
N
O
O
Br
Br
1) nBuLi
2) TsN3
71%
3) TBAF
  THF
78%
DIAD, PPh3
THF
N
N
N
N
DMAS
DMAS
N
N
N3
N3
N
N
Br
Br
O
O
O
O Br
Br
N
N
N
N
DMAS
DMAS
H
N
NH
N3
N3
HN
H
N
Br
Br
O
O
Br
Br
NaOH, H2O
THF
78%
80%
NH
N
N
HN
H
N
NH
N3
N3
HN
H
N
Br
Br
O
O
Br
Br
HCl
MeOH
67%
H2, Lindlar
51%
NH
N
N
HN
H
N
NH
H2N
H2N
HN
H
N
Br
Br
O
O
Br
Br
then TFA
·2TFA
84 85 86
87
79  
 
The authors reported that 
1H-NMR of synthetic nagelamide D did not match that of the naturally 
occurring material; moreover, they were unable to get original NMR data from Kobayashi in order to 
unravel this inconsistency. Lovely also mentioned [123] an unpublished biomimetic total synthesis of 
nagelamide D by Horne et al., whose spectroscopic data perfectly matched the ones from Lovely 
group. The question whether the assigned structure or Kobayashi’s NMR data are in error remains 
open (on the subject see also Usami [126]). 
 
4.2. Sceptrin 
 
Sceptrin (8) (Figure 8) was isolated in 1981 by Faulkner and Clardy [127] from Agelas sceptrum. It 
is a dimeric pyrrole imidazole alkaloid formally made up by two hymenidin (11) subunits. The 
biogenetic hypothesis derives sceptrin from hymenidin (11)  via  an enzyme-mediated [2+2]-
cycloaddition [127]. Mar. Drugs 2009, 7 
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Figure 8. Proposal for the biogenetic origin of sceptrin (8). 
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After some unfruitful attempts to synthesize sceptrin from urocanic acid derivatives [128], Baran 
[129] and Birman [130] independently reported the synthesis of racemic sceptrin in 2004; two years 
later, the first enantioselective synthesis of (-)-sceptrin was published (Scheme 23) [131]. Main 
hallmarks [132] of this approach are: 
(a)  minimal use of protecting groups (benzylamide proved to be crucial for a complete transfer of 
chirality); 
(b)  application of an oxaquadricyclane rearrangement/fragmentation [133] in natural product 
synthesis to diastereoselectively access the cyclobutane core of sceptrin;  
(c)  application of a new chemo- and regioselective halogenation method [134]; 
(d)  formation of 2-aminoimidazole in mild conditions [135] (these moieties were voluntarily 
introduced at a later stage of the synthesis because the earlier introduction of this step resulted 
in compounds intractability). 
 
Scheme 23. Baran’s total synthesis of (-)-sceptrin (8). 
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PLE = pig liver esterase, DMT-MM = 4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methylmorpholinium chloride. Mar. Drugs 2009, 7 
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Sceptrin has useful biological properties, like antibacterial and antiviral [136], antihistaminic and 
antimuscarinic activity [137–139]; besides, it is a natural inhibitor of somatostatin [140]. Recently, 
Rodriguez and his group, through bidirectional affinity experiments, identified sceptrin as being able 
to bind to MreB [141], a cell wall regulator, and thus a validated antibiotic target [142]. When sceptrin 
interacts with MreB, cell wall disruption was observed. 
 
5. Cyclic Dimers 
 
5.1. Ageliferin 
 
Ageliferins (9, 88 and 89, Figure 9) are dimeric pyrrole-imidazole alkaloids that have been isolated 
from the sponge Agelas conifera [136, 143]. This family of natural products showed antimicrobial and 
antiviral activity [136] as well as actomyosin ATPase activation [144]. Ageliferins, like the majority of 
alkaloids originated by sponges of the genus Agelas, are feeding deterrents. 
 
Figure 9. Ageliferins. 
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The chemical defence that sponges adopt against predatory reef fishes has been investigated and 
measured [42], revealing that ageliferins, together with their close relatives sceptrins, are responsible 
for deterrence in the sponge Agelas conifera. Biogenetically, ageliferin (9) was hypothesized to derive 
from hymenidin (11)  via  an enzyme-mediated [4+2]-cycloaddition that infers chirality to achiral 
precursors, as well as an enzyme-catalyzed [2+2]-cycloaddition generates sceptrin (8) [29] (Figure 10). 
 
Figure 10. Proposal for biogenetic origin for ageliferin (9). 
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Since its isolation and identification, several synthetic efforts aiming at the synthesis of 9 were 
based on this biogenetic hypothesis [3]. In 2004 Baran and co-workers speculated about the extracts 
composition of Agelas conifera [145] (Figure 11), in which sceptrin was dramatically more abundant 
than ageliferins [26]. If the two families of alkaloids derived from the same linear precursor via two 
different cycloaddition pathways, ageliferins should be thermodynamically more abundant than 
sceptrins in the extract. 
 
Figure 11. Extracts composition of Agelas conifera. Reproduced with permission from 
Verlag Z. Naturforsch. [145]. 
 
 
An alternative biogenetic pathway was then postulated involving a formal [1,3]-sigmatropic 
rearrangement of sceptrin followed by a double bond isomerisation [26, 132] (Figure 10). According to 
this hypothesis, the vinylcyclobutane of rac-sceptrin was efficiently converted into the cyclohexene 
core of rac-ageliferin under microwave irradiation and some speculations on the reaction mechanism 
have been reported [26]. Two years later, Baran and co-workers published the accomplishment of the 
total synthesis of (-)-sceptrin (8), whose subsequent microwave-mediated vinylcyclobutane 
rearrangement yielded the naturally occurring (-)-ageliferin (9)  (40% yield along with unreacted 
sceptrin) [131]. The scale-up of the reaction and the prolonged heating resulted in the formation of epi-
ageliferin, later christened nagelamide E (90) [122], which was synthesized for the first time [132, 
146] (Scheme 24).  
 
Scheme 24. Enantioselective synthesis of (-)-ageliferin (9) and (-)-nagelamide E (90). 
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Among the mechanistic speculations originally reported [26], the hypothesis of a 6-endo-trig 
recombination and olefin isomerization of the diradical intermediate deriving from the radical scission 
of the cyclobutane ring, showed to be more consistent with the observed partial stereochemical 
erosion.
 
A different approach to the core skeleton of ageliferin, as well as other oroidin cyclic dimers, has 
been reported by Chen et al. in 2006, who exploited a regiocontrolled Mn
III-mediated oxidative 
heterobicyclization of a β-ketoester for the construction of tricycle 91. The reaction proceeded through 
a 5-exo/6-endo radical cyclization pathway [147] (Scheme 25). 
 
Scheme 25. Chen approach to oroidin cyclic dimers core. 
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Hydrolysis of 91 revealed ageliferin core 92, which was oxidatively rearranged to massadine 
skeleton  93 despite epimerization at C15. Lactone 91 can be oxidized after removal of the TIPS 
protective group, generating the spiro-derivative 94 with opposite facial selectivity. Subsequent 
hydrolysis afforded intermediate 95, which bears the palau’amine spiro-skeleton, but opposite relative 
configurations at C2 and C15. 
In mid-2009 an alternative approach has been described by Lovely [148], who exploited a thermal 
intramolecular Diels-Alder (IMDA) on enyne 96 for the construction of the intermediate 97, which 
could be converted to ageliferins core 98 or, in turn, rearranged under oxidative conditions in the 
presence of Davis’ oxaziridine (99) to the palau'amine nucleus 100 (Scheme 26).  
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Scheme 26. IMDA approach to ageliferins and palau’amine cores.  
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5.2. Palau’amine 
 
The hexacyclic bisguanidine palau'amine (101) was isolated in 1993 by Scheuer and co-workers 
[149] from the sponge Stylotella agminata. It showed cytotoxicity against some tumor cell lines as 
well as antibiotic and antifungal activity. The relative configuration initially assigned (101a) to the 
structure implies a cis junction of the azabicylo[3.3.0]octane moiety and a cis relationship between the 
chlorine atom and the aminomethyl chain (Figure 12). 
 
Figure 12. Previously assigned (101a) and revised (101b) structure of palau’amine. 
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Later, while reporting the isolation and structure elucidation of tetrabromostyloguanidine (102) 
(also named carteramine A), Matsunaga [150] and Köck [151] raised the question for a revision of the 
assigned structure of palau'amine, according to NMR data and computational experiments on related 
compounds. Finally, in 2007 Quinn et al. [152] reported the correct structure of palau'amine (101b), 
entailing an inversion of configuration at C12, C17 and C20 (Figure 12) resulting in a 
thermodynamically less obvious trans-fused azabicylo[3.3.0]octane moiety and with the chlorine atom 
being trans to the vicinal aminomethyl chain. 
In 1998 Scheuer [22] proposed palau'amine as biogenetically arising from a Diels-Alder reaction 
between 11,12-dehydrophakellin (103) and 3-amino-1-(2-aminoimidazolyl)prop-1-ene, followed by a 
chloroperoxidase-catalyzed chlorination that initiates a 1,2-shift/ring contraction and water addition 
(Scheme 27). 
 
Scheme 27. Scheuer's proposal for biogenesis of palau'amine. 
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The revision of the structure of 101 exerted a profound influence on the biogenetic hypothesis 
concerning dimeric PIAs (see Subsection 1.1 and Figure 13). 
Since its isolation, efforts towards the total synthesis of palau'amine have been increasing [3]. 
Recently Baran et al. have reported the total synthesis of axinellamines [153] and massadines [154]. 
These achievements may represent the prelude for the completion of their own strategy toward 
palau'amine. 
Lovely  exploited an intramolecular  Diels-Alder approach (IMDA) for the construction of the 
intermediate 97 (see Scheme 26) that, after stereoselective double bond reduction, was subjected to an 
oxidative rearrangement thus securing the spiro-fused system of palau'amine (100). To this purpose 
Davis' reagent (99) [148] delivered better results than its ancestor dimethyldioxirane [155]. 
Chen reported a regiocontrolled Mn
III-mediated oxidative heterobicyclization of a β-ketoester 
yielding the spiro intermediate 95 after suitable modifications [147] (Scheme 25). 
Romo succeeded in the synthesis of the trans-fused azabicyclo[3.3.0]octane core of palau'amine by 
exploiting a biomimetic chlorination and a concomitant 1,2 shift/ring contraction of 104 for the 
construction of cis-fused intermediate 105 [27,156,157].  
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Figure 13. Structurally related PIAs cyclic dimers. 
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Subsequent selective deprotection, followed by simultaneous ring cleavage/epimerization with 
sodium methoxide afforded the anti-substituted cyclopentyl ester 106. Further manipulations yielded 
trans-azabicyclo[3.3.0]octane 107 [158] (Scheme 28).  
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Scheme 28. Romo’s approach to palau’amine core 107. 
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The tricyclic prolinol derivative 107 was envisioned to be a suitable substrate for the application of 
the oxidative annulation strategy that recently provided the first enantioselective synthesis of   
(+)-phakellin from prolinol by Romo’s group [159]. This approach would lead to the targeted 
palau'amine (101). 
Overman's approach foresees thiosemicarbazide annulation on a densely functionalized   
4,5-dihydropyrrole-2-carboxylate  108 as the key step for the assembly of a triazatriquinane 109, 
precursor of the cis-fused tetracyclic skeleton of epi-palau'amine [160]. Evolution of intermediate 109 
by means of a SmI2-mediated N-N bond reduction yielded 110.  
The following insertion of a spiro glycocyamidine ring, a subsequent TBAF-promoted cyclization 
for the assembly of the ketopiperazine moiety and further manipulations, resulted in the synthesis of 
hexacyclic congeners 111  and 112 of epi-palau'amine, bearing a cis configuration at the 
azabicyclo[3.3.0]octane core [161] (Scheme 29).  
Harran exploited a different approach to palau'amine following his biogenetic proposal which was 
based upon a spirocycloisomerization of tethered alkylidene glycocyamidines [23]. For this purpose, 
tetrahydropyridazine (113) has been acylated with acyl chloride 114 [160] and subsequently elaborated 
to intermediate 115, from which target monomer 116 was derived by mild thermolysis in the presence 
of HgCl2.  
Treatment of 116  with (i-PrCp)2TiCl2 prior to KHMDS, followed by exposure to 
FeCl2(DMF)3FeCl4, generated 117  as mixture of meso and C2  isomers. Hydrosilylation of 117, 
performed on the C2 isomer, and reduction mediated by proazaphosphatrane 118 yielded the partially 
debrominated bis-alkylidene derivative 119 that underwent spirocyclization in the presence of t-
BuOCl affording the spirocyclic core of palau'amine 120 [162] (Scheme 30). 
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Scheme 29. Overman’s synthesis of congeners 111 and 112 of epi-palau’amine. 
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Scheme 30. Harran's approach to palau'amine spirocyclic core 120. 
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5.3. Axinellamines 
 
Like palau’amine (101), axinellamines (121–124), massadines (125, 126) and stylissadines (2, 3) 
(Figure 13) are PIAs with a high degree of complexity and for this reason they are appealing targets 
for total synthesis.  
Axinellamines (121–124) were first isolated from Axinella sp. [163]. Their architecture is 
characterized by important stereogenicity (8 contiguous stereocenters) and a fully decorated 
cyclopentane ring. Moreover,  axinellamines B-D (122–124) display antibacterial activity against 
Helicobacter pylori, a bacterium implicated in pepticular and gastric cancer  (minimum inhibitory 
concentration (MIC) for bactericidal action against H. pylori at 1000 μM) [163]. Several papers have 
been published reporting synthetic efforts toward the synthesis of axinellamines and some of them 
have already been reviewed [2,3,7,147,164–166]. 
The key intermediate in the synthesis of axinellamines is the elaborated cyclopentane ring A 
(Figure 14), also common to palau’amine, massadine, styloguanidine (127, Figure 13) [167] and 
stylissadines. The first enantioselective synthesis toward an analogue of A, which  exploited the 
desymmetrization of 128, was reported by Carreira et al. in 2000 [165].  
 
Figure 14. Different approaches toward intermediate A. 
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Many approaches to this intermediate were envisioned and they can be classified into four main 
categories [30] (Figure 14): a) linear [23,147], b) ring contraction, [27,129,132,146,156,157,166, 
168–171], c) ring expansion (this approach still awaits experimental realization) [132]   
d) abiotic [160,165, 172–174]. Mar. Drugs 2009, 7 
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Scheme 31. Baran synthesis of key intermediate 131. 
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The first total synthesis of axinellamine A (121) and B (122) was completed by Baran et al. [153] in 
2008 starting from 129 and using an extremely straightforward approach. Key step was an oxidation 
(by means of Ag
II complex 132, Scheme 32), on polyfunctionalized intermediate 131. Both 
regioselectivity and overoxidation control of this reaction proved to be very impressive [34,153]. 
Synthesis of key intermediate 131 required 17 steps with an overall yield of 1.3% (Scheme 31). 
Starting from advanced intermediate 131, the synthesis of 121 and 122, as racemic mixture, was 
then completed in 6 steps and an overall yield of approximately 0.3% (Scheme 32). 
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Scheme 32. Completion of the axinellamine A (121) and B (122) total synthesis. 
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5.4. Massadines 
 
Starting from 130, Baran et al. synthesized also massadine (125) and massadine chloride (126), a 
precursor of the daunting stylissadines (Figure 13). 
Massadine was first isolated in 2003 from the marine sponge Stylissa aff. Massa [34]. Like the 
axinellamines, it is a dimeric pyrrole-imidazole alkaloid. Its peculiarity is due to the presence of a 
hydroxy group at C14 that renders this compound unique among the dimeric PIAs (Figure 13). 
Massadine (125) is biologically active as inhibitor of geranylgeranyltransferase type 1 from Candida 
albicans with IC50 of 3.9 μM [34]. A postulated biosynthetic precursor of 125 is massadine chloride 
(126), first isolated from Stylissa caribica [28]. Massadine chloride possesses a chlorine atom at C14, 
as in axinellamines (121–124) (C13), palau’amine (101) (C17) and tetrabromostyloguanidine (102) 
(C17) [151] (Figure 13).  
Syntheses of these alkaloids proved soon to be challenging due to the presence of many functional 
groups leading to several failed approaches [154]. Finally, 125 and 126, together with their unnatural 
C3,C7 epimers succumbed to total synthesis as reported in Scheme 33 [154].  
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Scheme 33. Synthesis of 125 and 126. 
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The key step of the synthesis was again the silver(II)-mediated oxidation reaction already reported 
in the synthesis of axinellamines (see Scheme 32). An optimization of the reaction conditions was 
necessary for massadines synthesis and led to the finding that TFA accelerates the oxidation, thus 
providing a general method to chemoselectively oxidize unprotected guanidines. Also the 
axinellamines synthesis overall yield was improved, obtaining 133 and 134 (Scheme 32), in shorter 
reaction times and at room temperature. The subsequent treatment of 135 with cyanamide required 
controlled pH conditions giving 136 along with its hydroxy analogue 137 (Scheme 33). The same 
reaction sequence was performed on both 136 and 137 leading to massadine chloride (126) and 
massadine (125) respectively, although each one associated with the corresponding C3,C7-epimer. Mar. Drugs 2009, 7 
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Both 126 and 3,7-epi-(126) can be converted to their hydroxy analogues, 125 and 3,7-epi-(125), in 
warm water, probably involving a nucleophilic substitution mechanism with retention of configuration 
via a massadine aziridine species [28].  
 
6. Cyclic Tetramers 
 
Stylissadines 
 
Stylissadines (2 and 3, Figure 1 and 13) are tetrameric members of PIAs. Structurally, they are 
ether-linked dimers of massadine and thus the largest and the most complex structures within the 
oroidin family of alkaloids discovered so far. Stylissadine A (2) is the formal condensation product of 
two molecules of massadine (125) and it has a C2 symmetry. Stylissadine B (3), on the contrary, does 
not have a C2 symmetry because the C-2’ stereocenter is inverted [175]. Both have biological activity 
(2: IC50 = 0.7 μM; 3: IC50 = 1.8 μM) as antagonists of the P2X7 receptor involved in inflammatory 
diseases, but their high molecular weight and structural complexity render them hard to develop as 
drugs [176]. Efforts to convert massadine chloride into stylissadines are underway in Baran’s group. 
 
7. Others 
 
Ageladine A 
 
In 2003, Fusetani et al. isolated the fluorescent alkaloid ageladine A (138) from the sponge Agelas 
Nakamurai by a bioassay-guided extraction [177]. Ageladine A is reported to inhibit several matrix 
metalloproteinases (MMPs-1, -2, -8, -9, -12 and -13). As it has been demonstrated that 138 does not 
chelate zinc ion like all known MMP-inhibitors do, the natural product probably operates with a 
completely different mechanism of action. Ageladine A showed also antiangiogenic effects. Moreover 
it is the first isolated PIA containing a 2-aminoimidazolopyridine moiety.  
In the same paper, Fusetani also hypothesized a possible biogenesis of ageladine A: amino acids 
proline and histidine evolve to dibromopyrrole carboxyaldehyde and histamine, respectively. They 
subsequently generate intermediate imine 139, which undergoes oxidative intramolecular cyclization 
to afford 138 (Figure 15). 
 
Figure 15. Proposed biogenesis for ageladine A (138). 
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Since its isolation, quite a few total syntheses have been reported and recently reviewed [7,8,10]. 
As shown in Figure 16, the first generation Weinreb approach toward 138 settled a 6π-1-azatriene 
electrocyclization as the key step [178,179], while a biomimetic synthesis was reported one year later 
by the same group exploiting a 6π-2-azatriene electrocyclization [180,181]. In the meantime Karuso et 
al. published an elegant, two-step, biomimetic synthesis of ageladine A starting from   
2-aminohistamine and 4,5-dibromo-2-formylpyrrole and moving through a Pictet-Spengler-type 
condensation [182]. 
 
Figure 16. Approaches to ageladine A (138). 
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An evaluation of the MMP-12 inhibition efficiency of ageladine A and its analogues has been 
reported by Ando and co-workers [183], confirming that the two bromine atoms and the NH groups 
are essential for the biological activity. Moreover very recently it has been demonstrated that 138 is a 
reliable and stable fluorescent pH sensor. Because of its permeability it can be used for detection of 
intracellular pH changes [184]. 
 
8. Conclusions  
 
Pyrrole-imidazole alkaloids (PIAs), a quite enlarged family of metabolites exclusively found in 
marine sponges, fascinate the scientific community for several reasons. Although the isolation of the 
first representatives of this family dates back to the ‘70s, new relatives continue to be unveiled, thus 
requiring a parallel fine-tuning in the speculations around their biogenesis and their ecological role in 
the sponges. Moreover, the quest to support hypotheses with experimental data, by increasing our 
knowledge in sponges’ biochemistry, proved to be encumbered by the difficulties in artificial sponge 
cell culturing. Challenges are also plentiful from a synthetic point of view. Architectural complexity, 
unusually high nitrogen content (N/C ≅ 1:2), structural revisions, unknown absolute stereochemistry 
are just some of the dreadful aspects one has to take into account while planning a total synthesis of 
these alkaloids. Those synthetic efforts however should not be considered just as simple intellectual Mar. Drugs 2009, 7 
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divertissements: some PIAs are gifted with promising biological activities, and larger availability of 
these compounds is key in developing more accurate pharmacological profiles. 
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